Here, we further analyzed the SMTA-OM results in both ALT+ and TEL+ cancer cells as well as the IMR90-S cells and demonstrated that the SMTA-OM alone can potentially be used to define the ALT positivity through the following readouts/parameters: (1) the presence and abundance of fusion/ITS+; (2) the presence and abundance of the fusion/ITS−; (3) the presence and abundance of TFEs; (4) the presence and abundance of super-long telomeres; and (5) the heterogeneity of telomere lengths at the whole-genome level. The gene discussed is GPT; the disease is cancer.